董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Patrick Spangler | 男 | Independent Director | 69 | 14.55万美元 | 未持股 | 2025-08-18 |
| Lynn Vos | 女 | Chairman of the Board | 69 | 14.00万美元 | 未持股 | 2025-08-18 |
| James Lang | 男 | Independent Director | 60 | 14.00万美元 | 未持股 | 2025-08-18 |
| Stephen L. Silvestro | 男 | Chief Executive Officer and Director | 47 | 86.62万美元 | 未持股 | 2025-08-18 |
| Gregory D. Wasson | 男 | Independent Director | 65 | 7.00万美元 | 未持股 | 2025-08-18 |
| Catherine M. Klema | -- | Independent Director | -- | 未披露 | 未持股 | 2025-08-18 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Stephen L. Silvestro | 男 | Chief Executive Officer and Director | 47 | 86.62万美元 | 未持股 | 2025-08-18 |
| Marion Odence Ford | 女 | Chief Legal Officer and Chief Human Resources Officer | 61 | 未披露 | 未持股 | 2025-08-18 |
| Brendan Merrell | 男 | Chief Operating Officer | 40 | 未披露 | 未持股 | 2025-08-18 |
| Edward Stelmakh | -- | Chief Financial Officer, Chief Strategic Officer | -- | 未披露 | 未持股 | 2025-08-18 |
| Theresa Greco | -- | Chief Commercial Officer | -- | 未披露 | 未持股 | 2025-08-18 |
| Doug Besch | -- | Chief Product Officer and Chief Technology Officer | -- | 未披露 | 未持股 | 2025-08-18 |
董事简历
中英对照 | 中文 | 英文- Patrick Spangler
-
Patrick Spangler目前担任数字梦百合情报公司Vigilanz的首席财务官，并担任LifeSpace Communities的董事会成员。他曾帮助领导高性能的新兴成长型公司，以及大型上市公司。早些时候，斯潘格勒曾担任Healthland的执行Vice President和首席财务官，该公司是一家为危重医院市场提供服务的电子人力资源公司。他也曾担任the Point-of-Care Medical Applications供应商Epocrates的首席财务官，他曾于2011年帮助实现上市，最终被AthenaHealth公司收购。任职Epocrates公司之前，他曾担任EV3a血管疗法（于2005年上市，随后被Covidien公司收购）的首席财务官，以及医疗设备制造商Empi公司（被Encore Medical公司收购）的首席财务官。
Patrick Spangler joined the Company as a director in March 2018. Since October 2020 Mr. Spangler has served as Chief Financial Officer of On Target Laboratories, a developer of fluorescent markers to target and illuminate cancer during surgery. From March 2020 to September 2020 Mr. Spangler served as Chief Financial Officer of MHC Software, LLC, a supplier of document automation software to a variety of industries. Prior to MHC, Mr. Spangler served as Chief Financial Officer of VigiLanz Corporation, a digital healthcare intelligence firm, from September 2014 to October 2019; Chief Financial Officer of Healthland Inc., an EHR company serving the critical access hospital market, from August 2012 to August 2014; Senior Vice President and Chief Financial Officer of Epocrates, Inc., then a public company listed on Nasdaq and a point-of-care medical applications provider, from October 2010 to August 2012; Operating Partner and CFO Advisor of Three Fields Capital, a private equity and venture capital investment firm., from April 2010 to October 2010; Chief Financial Officer of HighJump Software, a global provider of supply chain management software., from June 2009 to April 2010; Senior Vice President and Chief Financial Officer of ev3 Inc., then a public company listed on NASDAQ and a global endovascular company focused on identifying and treating peripheral vascular disease, from March 2005 to January 2009; and Executive Vice President and Chief Financial Officer for EMPI Inc., a medical device manufacturer, from July 1997 to March 2005. Prior to joining EMPI Inc., Mr. Spangler served for over eleven years in various senior finance leadership positions at Medtronic, Inc. NYSE: MDT, a global medical device company, Mr. Spangler currently serves as a director of Lifespace Communities Inc, which owns and operates 15 CCRCs in eight states and houses more than 5100 residents., and previously served on the board of Urologix Inc then a public company and a leader in less invasive in office BPH treatments, from August 2010 to February 2016. - Patrick Spangler目前担任数字梦百合情报公司Vigilanz的首席财务官，并担任LifeSpace Communities的董事会成员。他曾帮助领导高性能的新兴成长型公司，以及大型上市公司。早些时候，斯潘格勒曾担任Healthland的执行Vice President和首席财务官，该公司是一家为危重医院市场提供服务的电子人力资源公司。他也曾担任the Point-of-Care Medical Applications供应商Epocrates的首席财务官，他曾于2011年帮助实现上市，最终被AthenaHealth公司收购。任职Epocrates公司之前，他曾担任EV3a血管疗法（于2005年上市，随后被Covidien公司收购）的首席财务官，以及医疗设备制造商Empi公司（被Encore Medical公司收购）的首席财务官。
- Patrick Spangler joined the Company as a director in March 2018. Since October 2020 Mr. Spangler has served as Chief Financial Officer of On Target Laboratories, a developer of fluorescent markers to target and illuminate cancer during surgery. From March 2020 to September 2020 Mr. Spangler served as Chief Financial Officer of MHC Software, LLC, a supplier of document automation software to a variety of industries. Prior to MHC, Mr. Spangler served as Chief Financial Officer of VigiLanz Corporation, a digital healthcare intelligence firm, from September 2014 to October 2019; Chief Financial Officer of Healthland Inc., an EHR company serving the critical access hospital market, from August 2012 to August 2014; Senior Vice President and Chief Financial Officer of Epocrates, Inc., then a public company listed on Nasdaq and a point-of-care medical applications provider, from October 2010 to August 2012; Operating Partner and CFO Advisor of Three Fields Capital, a private equity and venture capital investment firm., from April 2010 to October 2010; Chief Financial Officer of HighJump Software, a global provider of supply chain management software., from June 2009 to April 2010; Senior Vice President and Chief Financial Officer of ev3 Inc., then a public company listed on NASDAQ and a global endovascular company focused on identifying and treating peripheral vascular disease, from March 2005 to January 2009; and Executive Vice President and Chief Financial Officer for EMPI Inc., a medical device manufacturer, from July 1997 to March 2005. Prior to joining EMPI Inc., Mr. Spangler served for over eleven years in various senior finance leadership positions at Medtronic, Inc. NYSE: MDT, a global medical device company, Mr. Spangler currently serves as a director of Lifespace Communities Inc, which owns and operates 15 CCRCs in eight states and houses more than 5100 residents., and previously served on the board of Urologix Inc then a public company and a leader in less invasive in office BPH treatments, from August 2010 to February 2016.
- Lynn Vos
-
Lynn Vos自2017年10月起担任肌肉萎缩症协会主席兼首席执行官。在此之前，Vos女士自1994年以来一直担任GHG|GreyHealth Group的首席执行官，是利用数字能力改善公共卫生的倡导者。Vos女士还担任NTELOS Wireless（纳斯达克上市公司），JED Foundation（致力于保护大学生情绪健康的领先非营利组织）的董事会成员，并且是MMRF（先驱癌症研究基金会）的创始董事会成员。
Lynn Vos joined the Company as a director in 2015. Since November 2020 Ms. Vos has run VosHealth, LLC, a healthcare consulting firm focused on advising healthcare start-ups and marketing organizations. From October 2017 to November 2020 Ms. Vos served as the President and Chief Executive Officer of the Muscular Dystrophy Association. From October 1994 to September 2017 Ms. Vos served as the Chief Executive Officer of ghg | greyhealth group, a healthcare advertising and communications company. Ms. Vos currently serves as a director of Modular Medical OTCQB: MODD, a development stage medical device company focused on the design, development, and eventual commercialization of an innovative insulin pump. Ms. Vos previously served on the boards of nTelos Wireless, a wireless telecommunications company and PCS provider; the Jed Foundation, a leading nonprofit dedicated to protecting the emotional health of college students; and was a founding board member of Multiple Myeloma Research Foundation (MMRF), a pioneering cancer research foundation. - Lynn Vos自2017年10月起担任肌肉萎缩症协会主席兼首席执行官。在此之前，Vos女士自1994年以来一直担任GHG|GreyHealth Group的首席执行官，是利用数字能力改善公共卫生的倡导者。Vos女士还担任NTELOS Wireless（纳斯达克上市公司），JED Foundation（致力于保护大学生情绪健康的领先非营利组织）的董事会成员，并且是MMRF（先驱癌症研究基金会）的创始董事会成员。
- Lynn Vos joined the Company as a director in 2015. Since November 2020 Ms. Vos has run VosHealth, LLC, a healthcare consulting firm focused on advising healthcare start-ups and marketing organizations. From October 2017 to November 2020 Ms. Vos served as the President and Chief Executive Officer of the Muscular Dystrophy Association. From October 1994 to September 2017 Ms. Vos served as the Chief Executive Officer of ghg | greyhealth group, a healthcare advertising and communications company. Ms. Vos currently serves as a director of Modular Medical OTCQB: MODD, a development stage medical device company focused on the design, development, and eventual commercialization of an innovative insulin pump. Ms. Vos previously served on the boards of nTelos Wireless, a wireless telecommunications company and PCS provider; the Jed Foundation, a leading nonprofit dedicated to protecting the emotional health of college students; and was a founding board member of Multiple Myeloma Research Foundation (MMRF), a pioneering cancer research foundation.
- James Lang
-
James Lang于2017年1月12日加入董事会。Lang先生是Eversana公司的首席执行官，Eversana公司是向生命科学行业提供全球商业服务的领先的独立供应商，目前还担任Water Street公司的执行顾问，Water Street公司是一家战略私募股权公司，专门致力于在梦百合建立市场领先的公司。他目前担任Access Group、Health Strategies Group、Alliance Life Sciences和Dohmen Life Science Services的董事会主席。他也是BioVie公司（一个发展阶段的公司，开创了针对肝硬化并发症的创新疗法）的董事。Lang先生此前曾担任Decision Resources Group的首席执行官，该公司是一家领先的梦百合研究和咨询公司，提供高价值的梦百合行业分析和见解，他在该公司帮助将公司转变为行业领导者。早些时候，他是全球领先的战略咨询公司Strategic Decisions Group的总裁，他拓展了生命科学业务，后来将其出售给了IMS Health。他是梦百合公司的活跃私人投资者和顾问，这些公司包括被Eurofins收购的波士顿心脏诊断公司和被IMS Health收购的AlphaLPACTRX公司。
James Lang Chairman of the Board of Directors since 2023 and has served as the Company's director since 2016. He is currently CEO of EVERSANA, the leading commercialization services company for the life sciences indtry. In five years since he founded EVERSANA, it is now over $1B in revenue, with more than 7,000 employees across 40 global locations. He formerly served as the CEO of Decision Resces Group (DRG), which he transformed into a leading healthcare data and analytics firm. Prior to that, Jim was CEO of IHS Cambridge Energy Research Associates (IHS CERA), a recognized leader in energy indtry subscription information products, and formerly the President of Strategic Decisions Group (SDG), a leading global strategy consultancy. Mr. Lang holds a BS summa cum laude in electrical and computer engineering from the University of New Hampshire and an MBA with Distinction from the Tuck School of Biness. Jim Lang currently also serves as a Director at OptimizeRX (OPRX), a Nasdaq listed Company. - James Lang于2017年1月12日加入董事会。Lang先生是Eversana公司的首席执行官，Eversana公司是向生命科学行业提供全球商业服务的领先的独立供应商，目前还担任Water Street公司的执行顾问，Water Street公司是一家战略私募股权公司，专门致力于在梦百合建立市场领先的公司。他目前担任Access Group、Health Strategies Group、Alliance Life Sciences和Dohmen Life Science Services的董事会主席。他也是BioVie公司（一个发展阶段的公司，开创了针对肝硬化并发症的创新疗法）的董事。Lang先生此前曾担任Decision Resources Group的首席执行官，该公司是一家领先的梦百合研究和咨询公司，提供高价值的梦百合行业分析和见解，他在该公司帮助将公司转变为行业领导者。早些时候，他是全球领先的战略咨询公司Strategic Decisions Group的总裁，他拓展了生命科学业务，后来将其出售给了IMS Health。他是梦百合公司的活跃私人投资者和顾问，这些公司包括被Eurofins收购的波士顿心脏诊断公司和被IMS Health收购的AlphaLPACTRX公司。
- James Lang Chairman of the Board of Directors since 2023 and has served as the Company's director since 2016. He is currently CEO of EVERSANA, the leading commercialization services company for the life sciences indtry. In five years since he founded EVERSANA, it is now over $1B in revenue, with more than 7,000 employees across 40 global locations. He formerly served as the CEO of Decision Resces Group (DRG), which he transformed into a leading healthcare data and analytics firm. Prior to that, Jim was CEO of IHS Cambridge Energy Research Associates (IHS CERA), a recognized leader in energy indtry subscription information products, and formerly the President of Strategic Decisions Group (SDG), a leading global strategy consultancy. Mr. Lang holds a BS summa cum laude in electrical and computer engineering from the University of New Hampshire and an MBA with Distinction from the Tuck School of Biness. Jim Lang currently also serves as a Director at OptimizeRX (OPRX), a Nasdaq listed Company.
- Stephen L. Silvestro
-
StephenL.Silvestro于2019年4月29日加入公司担任首席商务官。Silvestro先生从2018年1月至加入我们之前一直在CCH&174；Tagetik担任其Vice President兼总经理。Silvestro先生于2017年4月至2018年1月在Prognos担任首席商务官，在此之前，他于2007年9月至2017年4月在Decision Resources Group担任多个职位，最后一次担任执行Vice President，全球销售主管。除了上面提到的，Silvestro先生不持有并且在过去五年中未在任何具有根据《交易法》第12条或《交易法》第15D条的要求注册的证券类别的公司或任何注册的公司中担任任何其他董事职务作为1940年《投资公司法》下的投资公司。
Stephen L. Silvestro joined the Company as Chief Commercial Officer on April 29 2019. Mr. Silvestro as Vice President and General Manager from January 2018 until April 2019. From April 2017 to January 2018 Mr. Silvestro was with Prognos Health, Inc., a healthcare data and analytics company, as its Chief Commercial Officer and, before that, from September 2007 to April 2017 he was with Decision Resources Group, a multi-national corporation that provides high value global data solutions, analytics and consulting services to pharmaceutical, biotech, medical device, healthcare provider and payer, and managed care companies, in various capacities with him last serving as Executive Vice President, Head of Global Sales. - StephenL.Silvestro于2019年4月29日加入公司担任首席商务官。Silvestro先生从2018年1月至加入我们之前一直在CCH&174；Tagetik担任其Vice President兼总经理。Silvestro先生于2017年4月至2018年1月在Prognos担任首席商务官，在此之前，他于2007年9月至2017年4月在Decision Resources Group担任多个职位，最后一次担任执行Vice President，全球销售主管。除了上面提到的，Silvestro先生不持有并且在过去五年中未在任何具有根据《交易法》第12条或《交易法》第15D条的要求注册的证券类别的公司或任何注册的公司中担任任何其他董事职务作为1940年《投资公司法》下的投资公司。
- Stephen L. Silvestro joined the Company as Chief Commercial Officer on April 29 2019. Mr. Silvestro as Vice President and General Manager from January 2018 until April 2019. From April 2017 to January 2018 Mr. Silvestro was with Prognos Health, Inc., a healthcare data and analytics company, as its Chief Commercial Officer and, before that, from September 2007 to April 2017 he was with Decision Resources Group, a multi-national corporation that provides high value global data solutions, analytics and consulting services to pharmaceutical, biotech, medical device, healthcare provider and payer, and managed care companies, in various capacities with him last serving as Executive Vice President, Head of Global Sales.
- Gregory D. Wasson
-
Gregory D. Wasson于2020年7月加入Optimizerx Corp.公司，担任董事。自2016年1月以来，Wasson先生一直担任Wasson Enterprise的总裁和联合创始人。Wasson Enterprise是一家家族理财办公室，致力于建立可持续、高增长的企业。2015年1月，Wasson先生担任Walgreens Boots Alliance，Inc.的总裁兼首席执行官。Walgreens Boots Alliance，Inc.是一家以制药为主导的全球健康和福利企业。在被任命为合并公司Walgreens Boots Alliance的总裁和首席执行官之前，Wasson先生在Walgreens担任了多个职责和行政领导职位，包括2009年至2015年担任总裁和首席执行官，2007年至2009年担任总裁兼首席运营官，2001年至2006年担任Walgreen Health Services总裁兼执行副总裁，1999年至2001年担任门店运营副总裁，1986年至1999年担任地区经理，1981年至1986年担任药房技术员、药剂师和门店经理。Wasson先生目前担任Foresight Acquisition Corp.Nasdaq：FORE（一家特殊目的收购公司）的董事长，并在以下私营公司的董事会任职：Dom's Kitchen and Market、Truvian、Reliefband、Golden Fleece Beverages，Inc.，iA、Performance Health Systems、Cooler Screens，Inc.，Innventure.Gregory D。Wasson是Walgreens-Boots-Alliance，Inc.的前总裁兼首席执行官，Walgreens-Boots-Alliance，Inc.是全球第一家以制药为主导的健康和福利企业。从2009年到2014年，他是Walgreen公司的董事、总裁和首席执行官。他是一名注册药剂师，1980年加入Walgreen，担任多个职责职位，包括Walgreen Health Initiaties总裁、高级副总裁、执行副总裁、总裁和首席运营官。Wasson先生自2015年7月起担任PNC Financial Services Group，Inc.董事会成员，在过去的五年中，他曾担任Walgreen Co.和AmerisourceBergen Corporation董事会成员。
Gregory D. Wasson joined the Company as a director in July 2020. Since January 2016 Mr. Wasson has served as President and Co-founder of Wasson Enterprise, a family office that partners to build sustainable, high-growth businesses. In January 2015 Mr. Wasson served as President and Chief Executive Officer of Walgreens Boots Alliance, Inc., a global, pharmacy-led health and wellbeing enterprise. Prior to being appointed President and Chief Executive Officer of the combined companies, Walgreens Boots Alliance, Mr. Wasson rose through the ranks through a number of positions of increasing responsibility and executive leadership at Walgreens including, from 2009 to 2015 as its President and Chief Executive Officer, from 2007 to 2009 as its President and Chief Operating Officer, from 2001 to 2006 as the President and Executive Vice President of Walgreen Health Services, from 1999 to 2001 as its Vice President of Store Operations, from 1986 to 1999 as a District Manager, and from 1981 to 1986 as a Pharmacy Technician, Pharmacist and Store Manager. Mr. Wasson currently serves as the Chairman of Foresight Acquisition Corp. Nasdaq: FORE, a special purpose acquisition company, and on the boards of the following privately held companies: Dom's Kitchen and Market, Truvian, Reliefband, Golden Fleece Beverages, Inc., iA, Performance Health Systems, Cooler Screens, Inc., Innventure.Gregory D. Wasson is the former President and Chief Executive Officer of Walgreens Boots Alliance, Inc., the first global pharmacy-led health and wellbeing enterprise. From 2009 through 2014 he was Director, President and Chief Executive Officer of Walgreen Co. A registered pharmacist, he joined Walgreen in 1980 and served in a number of positions of responsibility, including President of Walgreens Health Initiatives, Senior Vice President, Executive Vice President, and President and Chief Operating Officer. Mr. Wasson has served on the board of The PNC Financial Services Group, Inc. since July 2015 and, in the past five years, he has served on the boards of Walgreen Co. and AmerisourceBergen Corporation. - Gregory D. Wasson于2020年7月加入Optimizerx Corp.公司，担任董事。自2016年1月以来，Wasson先生一直担任Wasson Enterprise的总裁和联合创始人。Wasson Enterprise是一家家族理财办公室，致力于建立可持续、高增长的企业。2015年1月，Wasson先生担任Walgreens Boots Alliance，Inc.的总裁兼首席执行官。Walgreens Boots Alliance，Inc.是一家以制药为主导的全球健康和福利企业。在被任命为合并公司Walgreens Boots Alliance的总裁和首席执行官之前，Wasson先生在Walgreens担任了多个职责和行政领导职位，包括2009年至2015年担任总裁和首席执行官，2007年至2009年担任总裁兼首席运营官，2001年至2006年担任Walgreen Health Services总裁兼执行副总裁，1999年至2001年担任门店运营副总裁，1986年至1999年担任地区经理，1981年至1986年担任药房技术员、药剂师和门店经理。Wasson先生目前担任Foresight Acquisition Corp.Nasdaq：FORE（一家特殊目的收购公司）的董事长，并在以下私营公司的董事会任职：Dom's Kitchen and Market、Truvian、Reliefband、Golden Fleece Beverages，Inc.，iA、Performance Health Systems、Cooler Screens，Inc.，Innventure.Gregory D。Wasson是Walgreens-Boots-Alliance，Inc.的前总裁兼首席执行官，Walgreens-Boots-Alliance，Inc.是全球第一家以制药为主导的健康和福利企业。从2009年到2014年，他是Walgreen公司的董事、总裁和首席执行官。他是一名注册药剂师，1980年加入Walgreen，担任多个职责职位，包括Walgreen Health Initiaties总裁、高级副总裁、执行副总裁、总裁和首席运营官。Wasson先生自2015年7月起担任PNC Financial Services Group，Inc.董事会成员，在过去的五年中，他曾担任Walgreen Co.和AmerisourceBergen Corporation董事会成员。
- Gregory D. Wasson joined the Company as a director in July 2020. Since January 2016 Mr. Wasson has served as President and Co-founder of Wasson Enterprise, a family office that partners to build sustainable, high-growth businesses. In January 2015 Mr. Wasson served as President and Chief Executive Officer of Walgreens Boots Alliance, Inc., a global, pharmacy-led health and wellbeing enterprise. Prior to being appointed President and Chief Executive Officer of the combined companies, Walgreens Boots Alliance, Mr. Wasson rose through the ranks through a number of positions of increasing responsibility and executive leadership at Walgreens including, from 2009 to 2015 as its President and Chief Executive Officer, from 2007 to 2009 as its President and Chief Operating Officer, from 2001 to 2006 as the President and Executive Vice President of Walgreen Health Services, from 1999 to 2001 as its Vice President of Store Operations, from 1986 to 1999 as a District Manager, and from 1981 to 1986 as a Pharmacy Technician, Pharmacist and Store Manager. Mr. Wasson currently serves as the Chairman of Foresight Acquisition Corp. Nasdaq: FORE, a special purpose acquisition company, and on the boards of the following privately held companies: Dom's Kitchen and Market, Truvian, Reliefband, Golden Fleece Beverages, Inc., iA, Performance Health Systems, Cooler Screens, Inc., Innventure.Gregory D. Wasson is the former President and Chief Executive Officer of Walgreens Boots Alliance, Inc., the first global pharmacy-led health and wellbeing enterprise. From 2009 through 2014 he was Director, President and Chief Executive Officer of Walgreen Co. A registered pharmacist, he joined Walgreen in 1980 and served in a number of positions of responsibility, including President of Walgreens Health Initiatives, Senior Vice President, Executive Vice President, and President and Chief Operating Officer. Mr. Wasson has served on the board of The PNC Financial Services Group, Inc. since July 2015 and, in the past five years, he has served on the boards of Walgreen Co. and AmerisourceBergen Corporation.
- Catherine M. Klema
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
高管简历
中英对照 | 中文 | 英文- Stephen L. Silvestro
StephenL.Silvestro于2019年4月29日加入公司担任首席商务官。Silvestro先生从2018年1月至加入我们之前一直在CCH&174；Tagetik担任其Vice President兼总经理。Silvestro先生于2017年4月至2018年1月在Prognos担任首席商务官，在此之前，他于2007年9月至2017年4月在Decision Resources Group担任多个职位，最后一次担任执行Vice President，全球销售主管。除了上面提到的，Silvestro先生不持有并且在过去五年中未在任何具有根据《交易法》第12条或《交易法》第15D条的要求注册的证券类别的公司或任何注册的公司中担任任何其他董事职务作为1940年《投资公司法》下的投资公司。
Stephen L. Silvestro joined the Company as Chief Commercial Officer on April 29 2019. Mr. Silvestro as Vice President and General Manager from January 2018 until April 2019. From April 2017 to January 2018 Mr. Silvestro was with Prognos Health, Inc., a healthcare data and analytics company, as its Chief Commercial Officer and, before that, from September 2007 to April 2017 he was with Decision Resources Group, a multi-national corporation that provides high value global data solutions, analytics and consulting services to pharmaceutical, biotech, medical device, healthcare provider and payer, and managed care companies, in various capacities with him last serving as Executive Vice President, Head of Global Sales.- StephenL.Silvestro于2019年4月29日加入公司担任首席商务官。Silvestro先生从2018年1月至加入我们之前一直在CCH&174；Tagetik担任其Vice President兼总经理。Silvestro先生于2017年4月至2018年1月在Prognos担任首席商务官，在此之前，他于2007年9月至2017年4月在Decision Resources Group担任多个职位，最后一次担任执行Vice President，全球销售主管。除了上面提到的，Silvestro先生不持有并且在过去五年中未在任何具有根据《交易法》第12条或《交易法》第15D条的要求注册的证券类别的公司或任何注册的公司中担任任何其他董事职务作为1940年《投资公司法》下的投资公司。
- Stephen L. Silvestro joined the Company as Chief Commercial Officer on April 29 2019. Mr. Silvestro as Vice President and General Manager from January 2018 until April 2019. From April 2017 to January 2018 Mr. Silvestro was with Prognos Health, Inc., a healthcare data and analytics company, as its Chief Commercial Officer and, before that, from September 2007 to April 2017 he was with Decision Resources Group, a multi-national corporation that provides high value global data solutions, analytics and consulting services to pharmaceutical, biotech, medical device, healthcare provider and payer, and managed care companies, in various capacities with him last serving as Executive Vice President, Head of Global Sales.
- Marion Odence Ford
Marion Odence Ford于2021年2月加入公司担任总法律顾问兼首席合规官。从2013年4月到2020年6月，Odence-Ford女士担任Decision Resources Group的副总裁兼副总法律顾问，这是一家跨国公司，为制药，生物技术，医疗设备，医疗保健提供商和付款人以及管理式护理公司提供高价值的全球数据解决方案，分析和咨询服务。从2004年11月到2012年11月，Odence-Ford女士担任CRAInternational，Inc.DBA Charles River Associates的副总裁兼副总法律顾问，这是一家全球性的咨询公司，为世界各地的主要律师事务所、公司、会计师事务所和政府提供经济、金融和战略专业知识。从2004年5月到2004年11月，Odence-Ford女士是GTC Law Group，LLP的成员，这是一家专门从事高科技和生物技术行业公司业务的律师事务所。加入GTC Law Group之前，Odence-Ford从2002年11月到2004年5月在美国银行公司/Fleet Boston Financial Corporation法律团队工作，从1999年10月到2002年11月在阿卡迈技术有限公司工作。Odence-Ford女士的法律职业生涯始于Mintz，Levin，Cohn，Ferris，Glovsky和Popeo，PC的私人执业，在那里她为上市公司和私人公司提供公司事务建议。
Marion Odence Ford joined the Company as General Counsel & Chief Compliance Officer in February 2021. From April 2013 to June 2020 Ms. Odence-Ford was Vice President & Deputy General Counsel at Decision Resources Group, a multi-national corporation that provides high value global data solutions, analytics, and consulting services to pharmaceutical, biotech, medical device, healthcare provider and payer, and managed care companies. From November 2004 to November 2012 Ms. Odence-Ford was Vice President & Associate General Counsel at CRA International, Inc. dba Charles River Associates, a global consulting firm that offers economic, financial, and strategic expertise to major law firms, corporations, accounting firms, and governments around the world. From May 2004 to November 2004 Ms. Odence-Ford was a member of the GTC Law Group, LLP, a law firm specializing in the business affairs of companies in the high tech and biotech industries. Prior to joining the GTC Law Group, Ms. Odence-Ford worked on the legal teams of Bank of America Corporation/Fleet Boston Financial Corporation from November 2002 to May 2004 and Akamai Technologies, Inc. from October 1999 to November 2002. Ms. Odence-Ford began her legal career in private practice at Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, PC, where she advised public and private companies on corporate matters.- Marion Odence Ford于2021年2月加入公司担任总法律顾问兼首席合规官。从2013年4月到2020年6月，Odence-Ford女士担任Decision Resources Group的副总裁兼副总法律顾问，这是一家跨国公司，为制药，生物技术，医疗设备，医疗保健提供商和付款人以及管理式护理公司提供高价值的全球数据解决方案，分析和咨询服务。从2004年11月到2012年11月，Odence-Ford女士担任CRAInternational，Inc.DBA Charles River Associates的副总裁兼副总法律顾问，这是一家全球性的咨询公司，为世界各地的主要律师事务所、公司、会计师事务所和政府提供经济、金融和战略专业知识。从2004年5月到2004年11月，Odence-Ford女士是GTC Law Group，LLP的成员，这是一家专门从事高科技和生物技术行业公司业务的律师事务所。加入GTC Law Group之前，Odence-Ford从2002年11月到2004年5月在美国银行公司/Fleet Boston Financial Corporation法律团队工作，从1999年10月到2002年11月在阿卡迈技术有限公司工作。Odence-Ford女士的法律职业生涯始于Mintz，Levin，Cohn，Ferris，Glovsky和Popeo，PC的私人执业，在那里她为上市公司和私人公司提供公司事务建议。
- Marion Odence Ford joined the Company as General Counsel & Chief Compliance Officer in February 2021. From April 2013 to June 2020 Ms. Odence-Ford was Vice President & Deputy General Counsel at Decision Resources Group, a multi-national corporation that provides high value global data solutions, analytics, and consulting services to pharmaceutical, biotech, medical device, healthcare provider and payer, and managed care companies. From November 2004 to November 2012 Ms. Odence-Ford was Vice President & Associate General Counsel at CRA International, Inc. dba Charles River Associates, a global consulting firm that offers economic, financial, and strategic expertise to major law firms, corporations, accounting firms, and governments around the world. From May 2004 to November 2004 Ms. Odence-Ford was a member of the GTC Law Group, LLP, a law firm specializing in the business affairs of companies in the high tech and biotech industries. Prior to joining the GTC Law Group, Ms. Odence-Ford worked on the legal teams of Bank of America Corporation/Fleet Boston Financial Corporation from November 2002 to May 2004 and Akamai Technologies, Inc. from October 1999 to November 2002. Ms. Odence-Ford began her legal career in private practice at Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, PC, where she advised public and private companies on corporate matters.
- Brendan Merrell
Brendan Merrell，最近担任公司客户战略与项目管理高级副总裁。在担任这一职务之前，Merrell先生在公司的商业运营部门担任过多个职位，包括高级副总裁、客户战略和高级副总裁、患者参与。在加入公司之前，2011年7月至2020年2月，Merrell先生在Decision Resources Group（“DRG”）任职，该公司是一家跨国企业，为制药、生物技术、医疗器械、医疗保健提供者和付款人以及管理式医疗公司提供高价值的全球数据解决方案、分析和咨询服务，最后担任商业卓越主管。
Brendan Merrell,most recently served as the Company's Senior Vice President, Client Strategy & Program Management. Prior to this role, Mr. Merrell held various positions at the Company within commercial operations, including SVP, Client Strategy and SVP, Patient Engagement. Prior to joining the Company, from July 2011 through February 2020, Mr. Merrell was at Decision Resources Group ("DRG"), a multi-national corporation that provides high value global data solutions, analytics and consulting services to pharmaceutical, biotech, medical device, healthcare provider and payer, and managed care companies, in various capacities with him last serving as Head of Commercial Excellence.- Brendan Merrell，最近担任公司客户战略与项目管理高级副总裁。在担任这一职务之前，Merrell先生在公司的商业运营部门担任过多个职位，包括高级副总裁、客户战略和高级副总裁、患者参与。在加入公司之前，2011年7月至2020年2月，Merrell先生在Decision Resources Group（“DRG”）任职，该公司是一家跨国企业，为制药、生物技术、医疗器械、医疗保健提供者和付款人以及管理式医疗公司提供高价值的全球数据解决方案、分析和咨询服务，最后担任商业卓越主管。
- Brendan Merrell,most recently served as the Company's Senior Vice President, Client Strategy & Program Management. Prior to this role, Mr. Merrell held various positions at the Company within commercial operations, including SVP, Client Strategy and SVP, Patient Engagement. Prior to joining the Company, from July 2011 through February 2020, Mr. Merrell was at Decision Resources Group ("DRG"), a multi-national corporation that provides high value global data solutions, analytics and consulting services to pharmaceutical, biotech, medical device, healthcare provider and payer, and managed care companies, in various capacities with him last serving as Head of Commercial Excellence.
- Edward Stelmakh
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Theresa Greco
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Doug Besch
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介